NCT04833257View on ClinicalTrials.gov

Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

GP combine with Tislelizumab neoadjuvant therapy+CCRT

chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER